MIRM250117C22500
- 0.00
- 0.000.00%
Mirum Pharmaceuticals Newsroom
Express News | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
JMP Securities Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $74
Would Mirum Pharmaceuticals (NASDAQ:MIRM) Be Better Off With Less Debt?
Mirum Shares Surge More Than 90% in 6 Months: Here's Why
Analysts Are Bullish on These Healthcare Stocks: Annexon Biosciences (ANNX), Mirum Pharmaceuticals (MIRM)
Express News | Mirum Pharmaceuticals Inc : JP Morgan Raises Target Price to $54 From $39
Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results
Evercore Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $68
Mirum Pharmaceuticals To Showcase Data From Its LIVMARLI And Volixibat Clinical Programs At AASLD's The Liver Meeting November 15-19, 2024
Mirum Pharmaceuticals Price Target Maintained With a $66.00/Share by HC Wainwright & Co.
Morgan Stanley Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $60
A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $50 to $70
Mirum Pharmaceuticals Is Maintained at Outperform by Baird
Mirum Pharmaceuticals Analyst Ratings
Promising Outlook for Mirum Pharmaceuticals: Buy Rating Justified by Strong Performance and Strategic Initiatives
Express News | Mirum Pharmaceuticals Inc : Morgan Stanley Raises Target Price to $60 From $59
Mirum Pharmaceuticals Reports Strong Q3 Sales Growth
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript Summary
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript
Mirum Pharmaceuticals | 8-K: Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update